
Provisions passed by the House last year that subjected insulin products to Medicare price negotiation and capped Medicare insulin copays at $35 per month have been left out of the latest draft of the bill.
Patents and other intellectual property rights allow the multinationals to evade competition for years on end, writes Faisal Chaudhry.